Unicycive Therapeutics (UNCY) Competitors

$0.46

+0.02 (+4.58%)

(As of 07/26/2024 ET)

UNCY vs. CELU, IMMX, ATRA, AVTE, DRRX, LSB, BTAI, PMN, CUE, and INAB

Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Celularity (CELU), Immix Biopharma (IMMX), Atara Biotherapeutics (ATRA), Aerovate Therapeutics (AVTE), DURECT (DRRX), Lakeshore Biopharma (LSB), BioXcel Therapeutics (BTAI), ProMIS Neurosciences (PMN), Cue Biopharma (CUE), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry.

Unicycive Therapeutics vs.

Unicycive Therapeutics (NASDAQ:UNCY) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

: Unicycive Therapeutics received 16 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 70.59% of users gave Unicycive Therapeutics an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Company Underperform Outperform
Unicycive Therapeutics Outperform Votes
24
70.59%
Underperform Votes
10
29.41%
Celularity Outperform Votes
8
42.11%
Underperform Votes
11
57.89%
: Unicycive Therapeutics currently has a consensus target price of $5.63, suggesting a potential upside of 1,130.85%. Given Unicycive Therapeutics' higher possible upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Celularity.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
0 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
3.20
Celularity
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: 40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 20.7% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Celularity has higher revenue and earnings than Unicycive Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Unicycive Therapeutics $680K 25.27 -$30.54M -$1.19 -0.38
Celularity $14.79M 4.11 $14.19M N/A N/A
: Company Net Margins Return on Equity Return on Assets
Unicycive Therapeutics N/A N/A -92.28%
Celularity N/A N/A N/A
: In the previous week, Unicycive Therapeutics had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 2 mentions for Celularity. Celularity's average media sentiment score of 0.63 beat Unicycive Therapeutics' score of 0.56 indicating that Celularity is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celularity
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Unicycive Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Company	Underperform	Outperform
Unicycive Therapeutics	Outperform Votes 24 70.59%	Underperform Votes 10 29.41%
Celularity	Outperform Votes 8 42.11%	Underperform Votes 11 57.89%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Celularity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	25.27	-$30.54M	-$1.19	-0.38
Celularity	$14.79M	4.11	$14.19M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	N/A	-92.28%
Celularity	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Unicycive Therapeutics beats Celularity on 10 of the 14 factors compared between the two stocks.

Ad DTI

We’re in a code red crisis and 99% of Americans are clueless

Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES!

And how YOU can prepare for the next 2024 BOOM here!

Get Unicycive Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export to Excel

Metric	Unicycive Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.55M	$7.09B	$5.32B	$8.21B
Dividend Yield	N/A	2.82%	2.72%	3.97%
P/E Ratio	-0.38	21.83	157.66	18.66
Price / Sales	25.27	318.38	2,090.54	91.84
Price / Cash	N/A	32.58	35.75	34.11
Price / Book	-4.15	5.89	4.95	4.51
Net Income	-$30.54M	$148.11M	$112.16M	$216.36M
7 Day Performance	14.25%	2.90%	2.71%	1.82%
1 Month Performance	12.81%	9.06%	6.96%	7.09%
1 Year Performance	-61.27%	4.24%	11.17%	4.89%

Unicycive Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	0 of 5 stars 0.00 / 5 stars	$3.02 -0.3%	N/A	-10.3%	$58.53M	$17.98M	0.00	220	Gap Up
IMMX Immix Biopharma	2.6725 of 5 stars 2.67 / 5 stars	$2.08 +1.5%	$10.50 +404.8%	+9.8%	$54.93M	N/A	-2.24	9	Analyst Forecast News Coverage
ATRA Atara Biotherapeutics	3.8851 of 5 stars 3.89 / 5 stars	$11.01 +4.8%	$355.50 +3,128.9%	-79.1%	$53.07M	$8.57M	-0.21	330	Short Interest ↓
AVTE Aerovate Therapeutics	3.4046 of 5 stars 3.40 / 5 stars	$1.78 -2.2%	$2.25 +26.4%	-88.0%	$51.30M	N/A	-0.59	20	Short Interest ↓ Positive News Gap Up
DRRX DURECT	3.2529 of 5 stars 3.25 / 5 stars	$1.59 +9.7%	$27.50 +1,629.6%	-46.6%	$49.35M	$8.55M	-1.67	80	Gap Down
LSB Lakeshore Biopharma	0 of 5 stars 0.00 / 5 stars	$0.49 -2.0%	N/A	N/A	$45.59M	$100M	0.00	773	Gap Up
BTAI BioXcel Therapeutics	4.4691 of 5 stars 4.47 / 5 stars	$1.17 -5.6%	$11.80 +908.5%	-88.9%	$43.91M	$1.38M	-0.23	90	Short Interest ↓
PMN ProMIS Neurosciences	2.3039 of 5 stars 2.30 / 5 stars	$2.09 -2.8%	$8.00 +282.8%	-48.9%	$39.63M	$10,000.00	-2.82	5	Short Interest ↑ News Coverage
CUE Cue Biopharma	4.1834 of 5 stars 4.18 / 5 stars	$0.76 -8.1%	$8.00 +950.8%	-82.3%	$37.03M	$5.49M	-0.72	60	Analyst Forecast Short Interest ↓ News Coverage
INAB IN8bio	3.475 of 5 stars 3.48 / 5 stars	$0.83 -1.8%	$10.00 +1,104.8%	-40.5%	$36.62M	N/A	-0.91	20	Short Interest ↓ Positive News